Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions
Current Oncology | Free Full-Text | Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer | Nature Reviews Clinical Oncology
The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immun
Phase 2 study of pembrolizumab in patients with advanced rare cancers | Journal for ImmunoTherapy of Cancer
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
Diapositive 1
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
Debio 1347-201 – Phase II basket trial in solid tumors harboring a fusion of FGFR1-3
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
Conceptual Framework for Therapeutic Development Beyond Anti–PD-1/PD-L1 in Urothelial Cancer | American Society of Clinical Oncology Educational Book
ESMO 2020 Preview, part 2: new and/or notable | BLU Ampersand, Inc.
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1 FGFR2 or FGFR3- (FUZE Clinical Trial) | Clinical Research Trial Listing ( Solid Tumor ) ( NCT03834220 )
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma | Journal for ImmunoTherapy of Cancer
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
Pharmaceuticals | Free Full-Text | TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs
Cancers | Free Full-Text | Changing Landscape of Systemic Therapy in Biliary Tract Cancer
Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - ScienceDirect
Cancers | Free Full-Text | Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm
Cells | Free Full-Text | New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review
Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy
